Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines

Nature

Volumn 446, Issue 7139, 2007, Pages 1000-1007

  Galonić, Danica P ^a   Gin, David Y ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAL; CANCER ANTIBODY; CARBOHYDRATE; CARBOHYDRATE ANTIGEN; CARBOHYDRATE DERIVATIVE; GANGLIOSIDE; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GLOBO H HEXASACCHARIDE; GLYCAN DERIVATIVE; GLYCOCONJUGATE; GLYCOSIDE; GLYCOSPHINGOLIPID; IMMUNOLOGICAL ADJUVANT; MUCIN ASSOCIATED GLYCAN; QS 21A; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN; CANCER; CARBOHYDRATE; CHEMOSYNTHESIS; VACCINE;

ACETALIZATION; ANTIGEN DETECTION; BREAST TUMOR; CANCER IMMUNOTHERAPY; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; DRUG CONJUGATION; DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EPITHELIUM TUMOR; GLYCOSYLATION; HUMAN; NONHUMAN; OVARY TUMOR; OXIDATION; PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 34247853422     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05813     Document Type: Review

References (94)

1. Feizi, T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314, 53-57 (1985).
2. Livingston, P. O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145, 147-166 (1995).
3. Hakomori, S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56, 5309-5318 (1996).
4. Fung, P. Y., Madej, M., Koganty, R. R. & Longenecker, B. M. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 50, 4308-4314 (1990).
5. Slovin, S. F., Keding, S. J. & Ragupathi, G. Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 83, 418-428 (2005).
6. Ouerfelli, O., Warren, J. D., Wilson, R. M. & Danishefsky, S. J. Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities. Expert Rev. Vaccines 4, 677-685 (2005).
7. Helling, F. et al. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 54, 197-203 (1994).
8. Helling, F. et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55, 2783-2788 (1995).
9. Kensil, C. R., Patel, U., Lennick, M. & Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146, 431-437 (1991).
10. Ragupathi, G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol. Immunother. 43, 152-157 (1996).
11. Livingston, P. O. et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12, 1036-1044 (1994).
12. MacLean, G. D., Reddish, M. A., Koganty, R. R. & Longenecker, B. M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emph. Tumor Immunol. 19, 59-68 (1996).
13. Slovin, S. F. et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA 96, 5710-5715 (1999).
14. Ragupathi, G. et al. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer 85, 659-666 (2000).
15. Ragupathi, G. et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 9, 5214-5220 (2003).
16. Slovin, S. F. et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21, 4292-4298 (2003).
17. Krug, L. M. et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. 10, 6094-6100 (2004).
18. Slovin, S. F. et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54, 694-702 (2005).
19. Ragupathi, G., Gathuru, J. & Livingston, P. Antibody inducing polyvalent cancer vaccines. Cancer Treat. Res. 123, 157-180 (2005).
20. Livingston, P. O. & Ragupathi, G. Cancer vaccines targeting carbohydrate antigens. Hum. Vaccin. 2, 137-143 (2006).
21. Toyokuni, T. & Singhal, A. K. Synthetic carbohydrate vaccines based on tumour-associated antigens. Chem. Soc. Rev. 231-242 (1995).
22. Danishefsky, S. J. & Allen, J. R. From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines. Angew. Chem. Int. Ed. 39, 836-863 (2000).
23. Brocke, C. & Kunz, H. Synthesis of tumor-associated glycopeptide antigens. Bioorg. Med. Chem. 10, 3085-3112 (2002).
24. Buskas, T., Ingale, S. & Boons, G. J. Glycopeptides as versatile tools for glycobiology. Glycobiology 16, 113R-136R (2006).
25. Paulsen, H. Advances in stereoselective chemical syntheses of complex oligosaccharides. Angew. Chem. Int. Ed. Engl. 21, 155-224 (1982).
26. Sinay, P. Recent advances in glycosylation reactions. Pure Appl. Chem. 63, 519-528 (1991).
27. Toshima, K. & Tatsuta, K. Recent progress in O-glycosylation methods and its application to natural products synthesis. Chem. Rev. 93, 1503-1531 (1993).
28. Schmidt, R. R. & Kinzy, W. Anomeric-oxygen activation for glycoside synthesis: the trichloroacetimidate method. Adv. Carbohydr. Chem. Biochem. 50, 21-123 (1994).
29. Garegg, P. J. Thioglycosides as glycosyl donors in oligosaccharide synthesis. Adv. Carbohydr. Chem. Biochem. 52, 179-205 (1997).
30. Davis, B. G. Recent developments in oligosaccharide synthesis. J. Chem. Soc. Perkin Trans. I 1, 2137-2160 (2000).
31. Hanessian, S. & Lou, B. Stereocontrolled glycosyl transfer reactions with unprotected glycosyl donors. Chem. Rev. 100, 4443-4464 (2000).
32. Nicolaou, K. C. & Mitchell, H. J. Adventures in carbohydrate chemistry: new synthetic technologies, chemical synthesis, molecular design, and chemical biology. Angew. Chem. Int. Ed. 40, 1576-1624 (2001).
33. Danishefsky, S. J. & Bilodeau, M. T. Glycals in organic synthesis: the evolution of comprehensive strategies for the assembly of oligosaccharides and glycoconjugates of biological consequence. Angew. Chem. Int. Ed. 35, 1380-1419 (1996).
34. Di Bussolo, V., Kim, Y.-J. & Gin, D. Y. Direct oxidative glycosylations with glycal donors. J. Am. Chem. Soc. 120, 13515-13516 (1998).
35. Shi, L., Kim, Y. J. & Gin, D. Y. C2-acyloxyglycosylation with glycal donors. J. Am. Chem. Soc. 123, 6939-6940 (2001).
36. Lemieux, R. U. & Ratcliffe, R. M. The azidonitration of tri-O-acetyl-d-galactal. Can. J. Chem. 57, 1244-1251 (1979).
37. Kan, C. et al. Photo amidoglycosylation of an allal azidoformate. Synthesis of β-2-amido allopyranosides. Org. Lett. 3, 381-384 (2001).
38. Di Bussolo, V., Liu, J., Huffman, L. G. & Gin, D. Y. Acetamidoglycosylation with glycal donors: a one-pot glycosidic coupling with direct installation of the natural C(2)-N-acetylamino functionality. Angew. Chem. Int. Ed. 39, 204-207 (2000).
39. Kannagi, R. et al. New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. J. Biol. Chem. 258, 8934-8942 (1983).
40. Bremer, E. G. et al. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J. Biol. Chem. 259, 14773-14777 (1984).
41. Hakomori, S. & Zhang, Y. Glycosphingolipid antigens and cancer therapy. Chem. Biol. 4, 97-104 (1997).
42. Bilodeau, M. T. et al. Total synthesis of a human breast tumor associated antigen. J. Am. Chem. Soc. 117, 7840-7841 (1995).
43. Park, T. K. et al. Total synthesis and proof of structure of a human breast tumor (globo-H) antigen. J. Am. Chem. Soc. 118, 11488-11500 (1996).
44. Zhu, T. & Boons, G.-J. A two-directional and highly convergent approach for the synthesis of the tumor-associated antigen globo-H. Angew. Chem. Int. Ed. 38, 3495-3497 (1999).
45. Douglas, N. L., Ley, S. V., Lucking, U. & Warriner, S. L. Tuning glycoside reactivity: new tool for efficient oligosaccharide synthesis. J. Chem. Soc. Perkin Trans. I 1, 51-66 (1998).
46. Burkhart, F., Zhang, Z., Wacowich-Sgarbi, S. & Wong, C.-H. Synthesis of the Globo H hexasaccharide using the programmable reactivity-based one-pot strategy. Angew. Chem. Int. Ed. 40, 1274-1277 (2001).
47. Zhang, Z. et al. Programmable one-pot oligosaccharide synthesis. J. Am. Chem. Soc. 121, 734-753 (1999).
48. Huang, C. Y. et al. Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc. Natl Acad. Sci. USA 103, 15-20 (2006).
49. Lassaletta, J. & Schmidt, R. R. Glycosyl imidates. Part 75. Synthesis of the hexasaccharide moiety of globo H (human breast cancer) antigen. Liebigs Ann. 1417-1423 (1996).
50. Bosse, F., Marcaurelle, L. A. & Seeberger, P. H. Linear synthesis of the tumor-associated carbohydrate antigens Globo-H, SSEA-3, and Gb3. J. Org. Chem. 67, 6659-6670 (2002).
51. Hakomori, S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer. Res. 52, 257-331 (1989).
52. Boons, G.-J. & Demchenko, A. V. Recent advances in O-sialylation. Chem. Rev. 100, 4539-4565 (2000).
53. Haberman, J. M. & Gin, D. Y. Dehydrative sialylation with C2-hemiketal sialyl donors. Org. Lett. 5, 2539-2541 (2003).
54. Castro-Palomino, J. C. et al. Efficient synthesis of ganglioside GM2 for use in cancer vaccines. Angew. Chem. Int. Ed. 36, 1998-2001 (1997).
55. Gordon, J. E. & Turrell, G. C. Observations on N- methylacetonitrilium and N-phenylbenzonitrilium hexachloroantimonates. J. Org. Chem. 24, 269-271 (1959).
56. Schmidt, R. R. & Ruecker, E. Stereoselective glycosidations of uronic acids. Tetrahedron Lett. 21, 1421-1424 (1980).
57. Hasegawa, A. et al. Synthetic studies on sialoglycoconjugates 25: reactivity of glycosyl promoters in α-glycosylation of N-acetylneuraminic acid with the primary and secondary hydroxyl groups in the suitably protected galactose and lactose derivatives. J. Carbohydr. Chem. 10, 493-498 (1991).
58. De Meo, C., Demchenko, A. V. & Boons, G. J. A stereoselective approach for the synthesis of α-sialosides. J. Org. Chem. 66, 5490-5497 (2001).
59. Hollingsworth, M. A. & Swanson, B. J. Mucins in cancer: protection and control of the cell surface. Nature Rev. Cancer 4, 45-60 (2004).
60. Hilkens, J., Ligtenberg, M. J., Vos, H. L. & Litvinov, S. V. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem. Sci. 17, 359-363 (1992).
61. Müller, S. & Hanisch, F. G. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J. Biol. Chem. 277, 26103-26112 (2002).
62. Marcos, N. T. et al. Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines. J. Histochem. Cytochem. 51, 761-771 (2003).
63. Banoub, J., Boullanger, P. & Lafont, D. Synthesis of oligosaccharides of 2-amino-2-deoxy sugars. Chem. Rev. 92, 1167-1195 (1992).
64. N antigen glycopeptide with a partial sequence of the 'tandem repeat' of the MUC-1 mucin. Angew. Chem. Int. Ed. 36, 618-621 (1997).
65. N- and T-antigen type O-glycopeptides and their conjugation to bovine serum albumin. Angew. Chem. Int. Ed. 98, 360-362 (1986).
66. Sames, D., Chen, X. T. & Danishefsky, S. J. Convergent total synthesis of a tumour-associated mucin motif. Nature 389, 587-591 (1997).
67. Paulsen, H., Rauwald, W. & Weichert, U. Building units of oligosaccharides. LXXXVI. Glycosidation of oligosaccharide thioglycosides to O-glycoprotein segments. Liebigs Ann. 75-86 (1988).
68. George, S. K. et al. Chemoenzymatic synthesis of sialylated glycopeptides derived from mucins and T-cell stimulating peptides. J. Am. Chem. Soc. 123, 11117-11125 (2001).
69. Svarovsky, S. A. & Barchi, J. J. Highly efficient preparation of tumor antigen-containing glycopeptide building blocks from novel pentenyl glycosides. Carbohydr. Res. 338, 1925-1935 (2003).
70. Rademann, J. & Schmidt, R. R. Solid-phase synthesis of a glycosylated hexapeptide of human sialophorin, using the trichloroacetimidate method. Carbohydr. Res. 269, 217-225 (1995).
71. n and T antigenic structures. Carbohydr. Res. 268, 17-34 (1995).
72. Nakahara, Y., Nakahara, Y. & Ogawa, T. Solid-phase synthesis of an O-linked glycopeptide based on a benzyl-protected glycan approach. Carbohydr. Res. 292, 71-81 (1996).
73. Winterfeld, G. A., Khodair, A. I. & Schmidt, R. R. O-glycosyl amino acids by 2-nitrogalactal concatenation - synthesis of a mucin-type O-glycan. Eur. J. Org. Chem. 1009-1021 (2003).
74. Elofsson, M., Salvador, L. A. & Kihlberg, J. Preparation of Tn and sialyl Tn building blocks used in Fmoc solid-phase synthesis of glycopeptide fragments from HIV gp120. Tetrahedron 53, 369-390 (1997).
75. Seitz, O. & Kunz, H. A novel allylic anchor for solid-phase synthesis - synthesis of protected and unprotected O-glycosylated mucin-type glycopeptides. Angew. Chem. Int. Ed. 34, 803-805 (1995).
76. Dziadek, S., Hobel, A., Schmitt, E. & Kunz, H. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. 44, 7630-7635 (2005).
77. Dziadek, S., Brocke, C. & Kunz, H. Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4. Chem. Eur. J. 10, 4150-4162 (2004).
78. Kensil, C. R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carr. Syst. 13, 1-55 (1996).
79. 13C NMR spectroscopy. Carbohydr. Res. 280, 1-14 (1996).
80. Zhu, X., Yu, B., Hui, Y. & Schmidt, R. R. Synthesis of the trisaccharide and tetrasaccharide moieties of the potent immunoadjuvant QS-21. Eur. J. Org. Chem. 965-973 (2004).
81. Nukada, T., Berces, A., Zgierski, M. Z. & Whitfield, D. M. Exploring the mechanism of neighboring group assisted glycosylation reactions. J. Am. Chem. Soc. 120, 13291-13295 (1998).
82. api. J. Am. Chem. Soc. 128, 11906-11915 (2006).
83. Garcia, B. A. & Gin, D. Y. Dehydrative glycosylation with activated diphenyl sulfonium reagents. Scope, mode of C(1)-hemiacetal activation, and detection of reactive glycosyl intermediates. J. Am. Chem. Soc. 122, 4269-4279 (2000).
84. Ishihara, K. & Yamamoto, H. Arylboron compounds as acid catalysts in organic synthetic transformations. Eur. J. Org. Chem. 527-538 (1999).
85. Nores, G. A., Dohi, T., Taniguchi, M. & Hakomori, S. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J. Immunol. 139, 3171-3176 (1987).
86. Zhang, S. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int. J. Cancer 73, 50-56 (1997).
87. Ragupathi, G. et al. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. J. Am. Chem. Soc. 128, 2715-2725 (2006).
88. Lo-Man, R. et al. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 64, 4987-4994 (2004).
89. Grigalevicius, S. et al. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjug. Chem. 16, 1149-1159 (2005).
90. Svarovsky, S. A., Szekely, Z. & Barchi, J. J. Synthesis of gold nanoparticles bearing the Thomsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen. Tetrahedron Asymmetry 16, 587-598 (2005).
91. Jiang, Z. H. & Koganty, R. R. Synthetic vaccines: the role of adjuvants in immune targeting. Curr. Med. Chem. 10, 1423-1439 (2003).
92. Buskas, T., Ingale, S. & Boons, G. J. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. Angew. Chem. Int. Ed. 44, 5985-5988 (2005).
93. Marciani, D. J. et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18, 3141-3151 (2000).
94. Marciani, D. J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8, 934-943 (2003).